Arsenic, Disordered Glucose Homeostasis and Atherosclerosis

Completed

Conditions studied: Atherosclerosis, Type 2 Diabetes (T2D)

In brief

Investigators will recruit 250 subjects; Group A will consist of 100 prediabetic patients with an A1c of 5.7%-6.4%. Group B will consist of 100 patients with uncontrolled T2D defined as either a) an A1c of 6.5%-7.9% without diabetes medications or b) an A1c ≥ 8.0% with or without diabetes medications. Group C will include 50 participants without T2D or known cardiovascular disease to serve as control comparisons.

Key facts

Study ID

NCT02759289

Run by

NYU Langone Health

People needed

279

Starts

2015-11-01

Expected to finish

2020-09-15

Last updated by the study team

2020-11-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• No known cardiovascular, cerebrovascular or peripheral arterial disease
• Able and willing to provide written informed consent for the study

You may not qualify if…

• Unable to speak Spanish or English
• Active smoking (within the past year)
• Autoimmune, rheumatologic or inflammatory disease
• Known active cancer receiving treatment
• Pregnancy
• Anemia (hemoglobin < 9 mg/dl)
• Chronic kidney disease (CrCl < 30ml/min)
• Known Coronary Artery Disease (CAD; prior stents or CABG)
• Congestive Heart Failure
• Known Peripheral Arterial Disease (PAD; lower extremity revascularization surgery OR lower extremity stenting)
• Known prior stroke or transient ischemic attack (TIA) (mini-stroke or temporary/transient stroke)

Where it is running

• New York University School of Medicine — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.